Diabetes I: Beyond Gestational DM

What is diabetes?

  • Diabetes is a Greek word meaning siphon - to pass through.

    • Mellitus, which is the common form we think of, is a Latin word meaning “sweet.” 

    • Insipidus, which is another form of diabetes we won’t talk about today, is a Latin word meaning “tasteless.” 

      • These terms refer to the effect of the disease on the urine, where mellitus is the passage of glucose through urine, making it sweet; while insipidus is unregulated water passing through urine, making it dilute.

  • Diabetes mellitus:

    • Around 8.8% of the world’s population has diabetes mellitus.

    • There are two main types.

      • Type 1 DM: this refers to a deficiency of insulin (10-15% of those with DM)

      • Type 2 DM: this refers to a resistance to insulin (85-90% of those with DM)

Type 1 Diabetes 

  • Insulin deficiency 

    • Thought to be primarily related to an autoimmune process leading to loss of pancreatic beta-cells.

  • Previously referred to as “juvenile diabetes” owing to predilection for onset in childhood:

    • 90,000 children diagnosed each year worldwide

    • Most common form of diabetes in those under age 15

      • Peak incidence at 12-14 years of age.

  • Has geographic predilection for Scandinavia, Europe, North America, and Australia. Incidence:

    • Over 10/100k in Europe, Russia, USA, Canada, Australia

    • Relatively rare in Asia - China, India, Middle East all <5/100k

  • Clinical onset of diabetes is marked by hallmark symptoms, and these are ultimate reason for diagnosis in >95% of cases:

    • Polydipsia (increased thirst)

    • Polyuria (increased urination)

    • Weight loss

    • Abdominal pain

    • Ketoacidosis (previous podcast!)

  • Given the insulin deficiency, treatment revolves around replacement of insulin with synthetic forms.

    • No successful studies thus far with immunologic interventions or preventive therapies.

Type 2 Diabetes

  • Acquired insulin resistance

    • This operates in three ways of pathophysiology:

      • Peripheral tissue insulin resistance: 

        • Overactivation of peripheral insulin receptors leads to downregulation - tissues are overextended.

      • Pancreatic beta cell dysfunction: 

        • Beta cells churning out loads of insulin - they get tired and “wear out.” 

      • Pancreatic alpha cell function increasing:

        • Hypothesized that the bar for hypoglycemia is raised physiologically - so inappropriate, early secretion of glucagon keeping blood sugars high.

    • T2DM’s insulin resistance is similar to gestational diabetes mellitus, where secretion of human placental lactogen creates an adaptogenic resistance to insulin (increasing glucose availability from the fetal perspective).

  • T2DM has a high prevalence worldwide, and is increasing.

    • A global pandemic of metabolic disease?!

      • Some estimate over 590 million worldwide will be affected by 2035.

      • Increasing prevalence worldwide, but most notable in US, Asia-Pacific, North Africa.

    • Highly associated with obesity - 90% of patients are obese or overweight at diagnosis.

      • Excess energy consumption combined with insufficient energy expenditure.

      • Generally adult-onset, but increasing prevalence in younger populations particularly with comorbid obesity.

  • Clinical onset is not typically acute:

    • Prediabetes often is manifest in these patients before diagnosis

      • 5-10% progress from prediabetes to T2DM annually.

      • Can be manifest for years-decade before progression.

    • Can manifest with similar acute symptoms to T1DM, but is most commonly insidious.

      • May be diagnosed incidentally with other healthcare-seeking, particularly major metabolic disease events (MI, stroke) or in seeking unrelated care (i.e., surgeries).

      • Common less acute presentations can include:

        • Fatigue, malaise

        • Infections (i.e., recurring genitourinary candidiasis)

        • Blurred vision

Some other, rarer forms of diabetes mellitus:

  • Latent autoimmune diabetes in adults (LADA) - a special type of DM that shares features with T1 and T2DM

    • Some may refer to this as “type 1.5” because of the mixed features:

      • Does not require insulin therapy for the first six months after diagnosis.

      • Typically acquired after age 35

      • Autoimmunity of T1DM - identifiable autoantibodies against pancreatic beta cells.

    • Depending on the stage in which they are identified or treated in their disease course, they may be responsive to oral insulin-sensitizing medications, or may require insulin.

  • Maturity Onset Diabetes of the Young (MODY) - hereditary form of DM with disruption of insulin production.

    • Typically an autosomal dominant inheritance:

      • Affected individuals have a 50% chance of passing to offspring.

    • Depending on the affected gene, hyperglycemia may be mild or severe, and treatment depends on which form of MODY a patient has.

    • Must be diagnosed before age 25.

  • Cystic fibrosis associated diabetes - given the failure of the exocrine pancreas in CF, most patients will develop a T1DM-like diabetes over time.

    • As therapies have gotten better for CF, some patients also develop T2DM features.

  • Steroid-associated diabetes - given hyperglycemia-inducing effects, those on chronic steroid therapy can develop diabetes akin to type 2 diabetes.

Diagnosing Diabetes Mellitus

  • Type 1 and type 2 diabetes 

    • Diagnosed according to the same ADA criteria for diabetes - one or more of:

      • Fasting glucose of > 126 mg/dL (with fasting defined as no caloric intake for at least 8 hours).

      • Glucose of > 200 mg/dL on a 2 hour, 75g oral glucose tolerance test (OGTT).

      • Hemoglobin A1c of > 6.5%.

      • Random glucose of > 200 mg/dL in a patient with classic hyperglycemia symptoms.

  • Prediabetes 

    • Diagnosed with any of the following:

      • Hemoglobin A1c of 5.7 - 6.4%.

      • Glucose of 140-199 mg/dL on a 2 hour, 75g OGTT.

      • Fasting glucose of 100-125 mg/dL

Complications of Diabetes

  • Acute

  • Chronic

    • Most of the major complications of diabetes that we think about result from chronic disease.

    • Many of the complications are due to microangiopathy, or damage to smallest blood vessels.

      • Excess blood glucose likely leads to incorporation of the excess sugar within capillary basement membranes.

      • This incorporation of excess sugar weakens the basement membranes, making them prone to micro-aneurysms.

      • When the microaneurysms rupture, new vessels and connective tissue must form, which causes sclerosis and narrowing of the arterioles surrounding the capillary.

      • This overall leads to worsened tissue perfusion and tissue function, and ultimately systemic hypertension.

    • Microangiopathy shows up everywhere:

      • Nephropathy

        • Damage to the renal glomeruli (capillaries of the kidney involved in filtration) worsen their filtering ability → glucosuria → microalbuminuria → CKD, renal failure, dialysis.

      • Neuropathy

        • Damage to the small vessels leading to nerve endings ultimately starves them of oxygen, impairing sensation.

          • This tends to develop in a “stocking and glove” form, affecting most distal extremities (smallest capillaries).

      • Retinopathy

        • Damage to small vessels in the retina, with growth of poor quality small new blood vessels (proliferative retinopathy) → macular edema → blindness 

          • Diabetic retinopathy is the most common cause of blindness among non-elderly adults in the world.

      • Sexual and reproductive dysfunction

        • Damage to small vessels leads to decreased sensation in women (and erectile dysfunction in men).

        • Infertility is more prevalent in patients with type 1 diabetes.

        • PCOS / oligo-ovulatory states are linked with insulin resistance and diabetes.

      • Encephalopathy

        • Linkage of diabetes and microvascular changes in the brain to cognitive decline, dementia.

    • Ultimately, this microangiopathy will contribute to the development of macroangiopathy, affecting larger blood vessels and complications such as:

      • Coronary artery disease → angina, myocardial infarction

      • Peripheral vascular disease → claudication, diabetic foot → amputation

      • Ischemic strokes

      • Hypertension

An Update on Pelvic Inflammatory Disease

We last covered PID and TOA on the podcast in February 2019 — and since then, as with our gonorrhea and chlamydia update, have some new updates to reflect the 2021 CDC Treatment Guidelines.

What is PID/TOA? 

  • PID: pelvic inflammatory disease 

    • This is a wide variety of inflammatory disorders of the upper female genital tract, including: 

      • Endometritis

      • Salpingitis

      • TOA: tubo-ovarian abscess

      • Pelvic peritonitis 

    • Caused by many infectious diseases. 

      • Most common: N. gonorrhoeae and C. trachomatis (gonorrhea and chlamydia)

        • 50% of PID diagnoses test positive for GC/CT, though this proportion is decreasing.

    • Other organisms that can be implicated:

      • Anaerobes, 

      • G. vaginalis 

      • H. influenzae

      • Enteric GNRs

      • Strep agalactiae

      • Cytomegalovirus 

      • Trichomonas (Trichomonas vaginalis)

      • Mycoplasima hominis and M. genitalium

      • Ureaplasma urealyticum

Diagnosis of PID

  • Can be difficult because of many vague symptoms, and some are asymptomatic 

  • Differential diagnosis is broad for abdominopelvic pain: 

    • Appendicitis 

    • Ectopic pregnancy

    • Ovarian torsion or ovarian cysts

    • Diverticulitis

    • Functional GI pain, IBS, IBD

    • Etc. etc. etc. 

  • A presumptive dx should be made, and treatment started,

    • In sexually active women and those at risk for STIs experiencing pelvic/lower abdominal pain, if no other cause for illness can be identified,

    • and if they have 1 or more of these minimum clinical criteria

    • Cervical motion tenderness 

    • Uterine tenderness 

    • Adnexal tenderness  

  • One or more of the following can be used to enhance specificity of the minimal clinical criteria: 

    • Oral temp > 101 F (38.3) 

    • Abnormal cervical mucopurulent discharge or friability 

    • Presence of abundant WBC on saline microscopy of vaginal fluid 

    • Elevated erythrocyte sedimentation rate 

    • Elevated C-reactive protein 

    • Laboratory documentation of cervical infection with N. gonorrhoeae or C. trachomatis 

  • Even more specific criteria can include:

  • Endometrial biopsy with histopathologic evidence of endometritis 

  • TVUS or MRI showing thickened, fluid-filled tubes with or without free fluid or tubo-ovarian complex

  • Laparoscopic findings of PID (Fitz-Hugh-Curtis syndrome

What should I do if I think someone has PID?

  • Testing:

  • HIV

    • Testing recommended by CDC “in all persons seeking STI testing who do not have a known diagnosis of HIV.” 

  • GC/CT

    • 50% will test positive, so they are high yield for PID testing.

    • NAAT testing is preferred method.

      • Patient self-collected swabs are just as accurate as clinician-collected.

      • First void urine is most sensitive; decreases with later voids during the day.

        • Urine testing may miss over 400k infections per year in USA - vaginal swab testing should be offered first, and patient-collected may help improve acceptability.

  • Imaging

    • Not recommended outright by CDC in PID evaluation.

    • Will frequently be part of your evaluation in a differential diagnosis

      • TVUS - may continue to have cervical motion tenderness, can demonstrate TOA. Can also demonstrate other GYN pathologies.

      • CT/MRI - unlikely to demonstrate specific findings for PID outside of large TOAs.

  • Treatment:

    • Primary Considerations: 

  • Choice of medication:

    • Treatment is empiric, requiring broad spectrum coverage of likely pathogens

    • All treatment types should be effective against gonorrhea and chlamydia 

  • Need for hospitalization:

    • Recommended if:

      • A surgical emergency (ie. appendicitis) cannot be excluded

      • Presence of tubo-ovarian abscess 

      • Pregnancy

      • Severe illness including nausea, vomiting, or high fever,

      • Inability to tolerate or follow outpatient regimen

      • Failed outpatient therapy based on follow up

    • Parenteral treatments

      • Ceftriaxone (1g IV q24 hrs) + doxycycline (100 mg oral or IV q12hrs) + metronidazole (500mg oral or IV q12h).

      • Cefoxitin (2g IV q6hrs) + doxycycline (100mg oral or IV q12hrs) 

      • Cefotetan (2g IV q12h) + doxycycline (100mg oral or IV q12hrs)

    • Because of pain associated with IV infusion, doxycycline should be given orally whenever possible.

    • Oral and IV doxycycline and metronidazole have similar bioavailability

  • Alternative regimens pending allergies and antibiotic availability:

    • Clindamycin (900 mg IV q8hrs) + gentamicin (2mg/kg loading dose IV or IM, then maintenance of 1.5mg/kg every 8 hrs, or single daily dosing of 3-5mg/kg) 

    • Ampicillin-sulbactam (Unasyn) 3g IV q6hrs + doxycycline 100mg q12hrs  

  • Goal of parenteral therapy will be to transition to oral antibiotics within 24-48 hours if clinical improvement.

    • Those with TOA should have at least 24 hours of inpatient observation

    • IM/Oral treatment - For continuation of inpatient treatment, or start here in those with mild-to-moderate symptoms of acute PID. 

  • Clinical outcomes are similar to those treated with IV therapy, but if women don’t respond in 72 hours, should be re-evaluated and treated with IV

    • Ceftriaxone 500mg IM x1 + doxycycline 100mg BID x14 days + metronidazole 500 mg BID x14 days 

    • Cefoxitin 2g IM + Probenecid 1g orally + doxycyline 100mg BID x14 days + metronidazole 500mg BID x14 days 

    • Some other 3rd generation cephalosporin + doxy + metronidazole 

  • If starting with outpatient treatment, improvement should be documented by follow up within 72 hours.

    • If no improvement has occurred, then hospitalization, assessment of the antimicrobial regimen, and considering potential additional diagnostics (imaging, laparoscopy) are indicated.

  • Retesting should occur at 3 months after treatment, regardless of treatment of sex partners, to assess for reinfection.

    • Patients should refrain from sex until treatment is completed, symptoms resolved, and sex partners have been treated.

    • Sex partners within previous 60 days of patients with PID should also be treated presumptively for gonorrhea and chlamydia

      • This is regardless of PID etiology or pathogens isolated 

      • Consider expedited partner therapy (EPT).

Managing TOAs 

  • Surgical drainage indicated if:

    • Failure to respond to treatment within 48-72 hours 

    • Clinical decline (ie. becoming septic) 

  • Likelihood of need for surgical intervention is related to the size of TOA: 

    • 60% of those with abscess >10cm 

    • 30% in 7-9cm 

    • 15% in those of 4-6 cm

Special considerations for treatment in certain populations:

  • Pregnancy

    • Pregnant patients with PID are at high risk of morbidity, pregnancy loss, preterm delivery.

    • Hospitalization and consultation with ID are recommended.

  • Persons with HIV

    • Patients with HIV may be more likely to have TOA, though symptoms are similar overall to those without HIV.

    • No data currently to suggest more aggressive therapy is needed in patients with HIV.

  • If patient has an IUD:

    • IUD is not required to be removed with a diagnosis of PID.

    • However, if there is no clinical improvement in 48-72 hours, then should consider removing the IUD.

Systemic Lupus Erythematosus, Part II: Treatment


So how do we manage lupus in pregnancy? 

  • Medications 

    • Hydroxychloroquine

      • Can decrease disease activity, prednisone use, and adverse pregnancy outcomes.

      • SMFM: We recommend that all patients with SLE, other than those with quiescent disease, either continue or initiate HCQ in pregnancy. 

      • ACR: conditionally recommends starting HCQ in pregnant patients with SLE who are not on it.

      • Some investigators recommend that patients with quiescent disease who have anti-SSA, anti-SSB, or APLS to consider starting HCQ because some studies suggest improved maternal and fetal outcomes in this specific population.  

    • Corticosteroids 

      • Recommended where SLE is not controlled simply with HCQ 

      • Un-fluorinated corticosteroids are largely inactivated by the placenta and preferred:

        • Prednisone, hydrocortisone, prednisolone.

      • Recent evidence suggests corticosteroids are not associated with fetal malformations 

      • However, steroids use can increase risk of gestational diabetes, preeclampsia, FGR, PPROM and PTB 

    • Other immunosuppressive agents 

      • Azathioprine - ok to use, not usually associated with fetal teratogenicity 

      • Cyclosporine - can also be used for refractory lupus flares 

      • Tacrolimus - calcineurin inhibitor - can be used, and has been reported to be more effective than cyclosporine 

    • What should I avoid? 

      • Prolonged use of NSAIDs - can lead to oligohydramnios, increased risk of NEC, premature closure of ductus arteriosus, and pulmonary hypertension 

      • Methotrexate discontinue 1-3 months prior to pregnancy due to teratogenicity 

      • Mycophenolate discontinue at least 6 weeks before attempting pregnancy 

      • Leflunomide - teratogen, and pregnancy should be delayed 2 years after use because of its long half-life and enterohepatic circulation 

    • Biologics 

      • There have been a lot used recently, including TNF-alpha inhibitors (ie. certolizumab, infliximab, adalimumab, golimumab) and other biologics 

      • Certolizumab can be safely used throughout pregnancy 

      • Decision to initiate or continue biologics should be made in collaboration with rheumatology and also be individualized for each patient

What about antenatal considerations? 

  • APLS 

    • If someone has met clinical and laboratory criteria for APLS, goal is to improve maternal, fetal, and neonatal outcomes.

    • For those who have not had previous thrombotic event: recommend prophylactic anticoagulation during pregnancy + 6 weeks postpartum 

    • For those with history of thrombotic event: recommend therapeutic anticoagulation throughout pregnancy + 6 weeks postpartum 

  • Antiphospholipid antibodies without APLS 

    • Patients with antibodies, especially lupus anticoagulant, who don’t meet clinical criteria for APLS remain at risk for preeclampsia

      • The risk of other adverse pregnancy outcomes and optimal management remains unclear 

    • Meta-analysis of those with asymptomatic APL antibodies with or without SLE found no difference in adverse pregnancy outcomes in those who had prophylactic treatment (aspirin) and those who did not 

    • SMFM recommend treatment with low-dose aspirin alone (i.e., no prophylactic anticoagulation)

  • SSA, SSB antibodies 

    • Given risk of neonatal lupus syndrome with or without SLE in those with these antibodies, recommendation is to treat 

    • Treatment with HCQ throughout pregnancy has been proposed to decrease the occurrence of congenital heart block in at-risk fetuses 

      • However, data is still lacking due to adequately powered clinical trials 

    • Another method proposed is to screen for 1st and 2nd degree heart block with echocardiograms, and then use steroids to try and prevent 3rd degree heart block 

      • However, in the PR Interval and Dexamethasone Evaluation (PRIDE) study, they showed that treatment with dexamethasone in some women did reverse first degree heart block 

        • However, some first degree heart block resolved on its own 

        • Several cases of complete heart block occurred without a graded progression through 1st and 2nd degree heart block 

      • There is some retrospective data as well to look at this, but overall, the utility of screening for or treating early heart block remains unproven 

      • Current studies ongoing = STOP BLOQ (Surveillance and Treatment to Prevent Fetal AV Block Likely to Occur Quickly)

    • Current recommendation: steroids should not be used routinely for treatment of fetal heart block due to anti-SSA/SSB antibodies given their unproven benefits nad known risks 

    • Serial fetal echos for assessment of PR interval not be routinely performed in patients with anti-SSA or SSB antibodies outside of clinical trial settings 

    • Doppler assessment of fetal heart rate during routine prenatal visits can be used to screen for fetal complete heart block 

  • Mild lupus flares 

    • Clinical and lab evaluation of possible SLE flare 

      • Physical exam, CBC, anti-dsDNA, complement levels 

      • Start HCQ 200 mg BID, if not already on it 

      • If already on it, can increase to 400 mg 2x/day 

      • If not responding, then can start 15-20 mg of prednisone a day.

  • Severe lupus flares 

    • Same clinical and lab evaluation 

    • Can also look for preeclampsia 

    • Start glucocorticoid dosage 1.0-1.5 mg/kg, then tapered per improvement 

    • Hospitalization may be needed 

    • Rheumatology consultation 

Other recommendations in pregnancy and labor

  • Pre-pregnancy counseling 

    • Patients with SLE should get prepregnancy counseling with MFM and rheumatology - discuss risks for both mom and fetus 

    • In those with severe maternal risk, pregnancy should be discouraged 

      • Active nephritis

      • Severe pulmonary, cardiac, renal, or neurologic disease

      • Recent stroke

      • Pulmonary hypertension 

  • Antenatal Testing

    • Antenatal testing and serial growth scans recommended in patients with SLE due to increased risk of FGR and stillbirth 

      • Currently no evidence to support optimal approach 

      • Usually, will start interval growths at 28 and assess every 4 weeks 

      • Fetal surveillance may start at around 32 weeks 

  • Delivery considerations 

    • Timing, mode, and management of delivery should be individualized 

    • If uncomplicated, early delivery is not recommended, but can be considered at term - ie. at 39 weeks 

    • If other complications, should manage per complication

    • Stress dose steroids in those with prolonged use of steroids 

  • Postpartum management 

    • Incidence of relapse or flare will increase in SLE - as with other autoimmune disease 

    • Can discuss with rheumatology regarding treatment postpartum - not all patients will need prophylactic treatment 

    • NSAIDs can be used for joint pain  

    • Can breastfeed if desired (NSAIDs, HCQ, and corticosteroids are considered compatible by AAP) 

  • Contraception 

    • LARCs such as IUD (with or without levonorgestrel) and etonogestrel implants are good options for patients with SLE 

    • Estrogen-containing oral contraceptives pose a theoretical risk for SLE flares 

      • Can be used in patients with SLE 

      • However, patients with history of active and severe SLE were excluded from randomized trials proving estrogen safety in those with SLE 

      • Contraindicated in those with previous thrombosis or those with APLS  

    • Progesterone only contraception is also safe

SECURE Act 2.0: Financial Updates with Michael Foley

Today we’re back again with Michael Foley, talking us through the new SECURE Act 2.0 as well as some new updates in disability insurance and student loan spaces.

Michael is a comprehensive financial advisor who runs his practice out of Scottsdale, Arizona, under North Star Resource Group. Michael was trained at Duke University and holds his Certified Financial Planner designation alongside his Certified Student Loan Professional designation. Although Michael serves a diverse group of clients with their financial and student loan needs, with two physician parents, Michael has found a specialty in working with those in the healthcare space. Michael is a registered representative and investment advisor representative of Securian Financial Services. Financial Professionals do not provide tax advice and this should not be considered as such. Please consult a tax professional for advice regarding your specific situation. Securities and investment advisory services offered through Securian Financial Services, Inc. Member FINRA/SIPC. North Star Resource Group is independently owned and operated. 6720 N Scottsdale Rd Ste 290, Scottsdale, AZ 85253.

You can schedule an initial consultation with Michael’s team at this link, or with their DI specialist, Hannah, at this link.

Systemic Lupus Erythematosus, Part I: Diagnosis and Risks

Reading: SMFM Consult Series #64: SLE in Pregnancy

What is systemic lupus erythematosus?

  • Definition

    • Chronic, multisystem, inflammatory autoimmune disease characterized by relapses and remission

    • Many organs can be involved and manifestations are variable between individuals

  • Why do we care about SLE in pregnancy?

    • The prevalence of SLE is about 28-150/100,000 individuals

    • More prevalent in females than males; often affects young adults, so it is a condition that can be encountered in pregnant individuals – currently 3300 deliveries per year are in people with SLE

How do we diagnose lupus?

  • Lupus = a syndrome and diagnosis requires presence of characteristic clinical features + confirmatory laboratory studies

    • Unfortunately, there are broad clinical manifestations, lack of pathognomic features or lab tests

    • Usually, you won’t have to diagnose lupus and someone will come into pregnancy already with the diagnosis

    • However, knowing the diagnostic criteria can be helpful in recognizing individuals who may have lupus

    • Can help the patient have faster recognition + referral to rheumatology

  • Diagnostic criteria – will include 2

    • From The European Alliance of Associations for Rheumatology (EULAR) – sensitivity of 96%, specificity is 93%

    • From the Systemic Lupus International Collaborating Clinics (SLICC) – sensitivity is 97%, specificity is 84%

smfm sTATEMENT ON sle; eular cRITERIA FOR sle

smfm; slicc criteria for sle

smfm; aplas criteria

Pregnancy and lupus

  • Increased maternal morbidity and mortality

    • Complications include nephritis, hematologic complications, neurologic abnormalities

    • Several fold increased risk of thrombosis, thrombocytopenia, infection, multiorgan disease

    • Pregnancy can also increase risk of disease flare, and 15-30% of flares are severe, and some can be life-threatening  

  • Lupus nephritis

    • Active renal disease is defined as >1g/day of proteinuria or GFR <60 in non-pregnant state

    • There is increased risk of permanent renal damage if GFR going into pregnancy is <40 or creatinine is >/= 1.5 mg/dL

    • One issue: difficult to differentiate lupus nephritis from preeclampsia

      • We discussed this in our episode “Imitators of Pre-eclampsia”

      • Features more common with lupus flare and less likely to be preeclampsia: increased anti-dsDNA ab, decreased levels of complements, usually will not have thrombocytopenia or elevated LFTs

      • Also, kidney biopsy that showed glomerulendotheliosis can yield a definitive diagnosis

      • Important to differentiate because the treatment for lupus nephritis can be medical, while severe preeclampsia may require delivery à if we don’t differentiate, could deliver extremely premature infant with no need

  • Hematologic Complications

  • Central Nervous System and Neurologic Complications

    • Can include headache, seizures, neuropathy, chorea, cerebritis, and even psychosis

    • CNS vasculitis is the most serious CNS disorder  

  • Other organ manifestation:

    • Cutaneous lupus erythematousus

    • Can also affect bones, joints, lungs, heart

  • So… how does all this affect pregnancy?

    • Obstetric outcomes:

      • 3x increased risk of pregnancy loss; however, if well controlled, risk ranges from 8-32%, which may not be substantially different from rates reported in the general obstetrical population for early pregnancy loss

      • Increased risk of preeclampsia: 15-35%

        • Risk is highest in those with active disease at time of conception, renal disease, chronic hypertension, those on high-dose prednisone, or those with APLS antibodies  

        • Prevention: low dose aspirin beginning at 12 weeks of gestation until delivery to decrease risk of preeclampsia

    • Fetal outcomes:

      • Risk of fetal growth restriction is 6-35% depending on the study

      • Increased risk of preterm birth, ranging from 19%-49%

        • The risk of preterm birth is associated with increased disease activity at time of conception, nephritis, chronic hypertension, and APLS antibodies

    • Neonatal complications 

      • Occurs in 1/20,000 live births, so it is rare but it is a serious complication

      • Caused by antibodies that can cross the placenta, usually anti-SSA, though anti-SSB antibodies can also cause this

      • Manifestations include skin lesions, congenital heart block, anemia, hepatitis, and thrombocytopenia

        • Skin lesions occur in approximately 50% of affected infants

      • Recurrence risk in patients with history of neonatal lupus and positive antibodies is 15-20% 

      • Because it is due to antibodies, skin, hematologic manifestations, and hepatitis usually resolves 3-6 months after birth; however, congenital heart block will not resolve as SSA antibodies lead to fibrosis of myocardial tissue and conduction system